Morningstar

Medpace Holdings: Healthy Outsourcing Demand Supports Strong Growth; $227 Fair Value Estimate

""
Securities In This Article
Medpace Holdings Inc
(MEDP)

Medpace Holdings Inc MEDP is a clinical contract research organization. It is engaged in scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. It is a full-service outsourcing model, providing services focused on the development, management and execution of clinical trials. As part of this full-service approach, the Company utilizes centralized systems, customer interface technology, support functions and processes that cross-service offerings and align resources to deliver efficient clinical trial services. It operates in North America, Europe, Africa, Asia, South America, Africa and Australia.

The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar’s editorial policies.

More in Stocks

Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue

Estee Lauder, Kraft Heinz, and Dollar General are our top consumer defensive stocks.
Erin Lash, CFA

Industrials: Many Stocks Overvalued After Q3 Outperformance

Our top stocks in this sector are Chart Industries, Wesco, and CNH Industrial.
Brian Bernard, CFA, CPA

Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities

In this sector, our favored stocks are Albemarle, Dow, and FMC.
Andrew Bischof, CFA and Travis Miller

About the Author

Rachel Elfman

Equity Analyst
More from Author

Rachel Elfman is an equity analyst for Morningstar Research Services, a wholly owned subsidiary of Morningstar, Inc. She covers contract research organizations and biotechnology stocks.

Before joining Morningstar in 2018, Elfman held multiple finance internships within private equity, wealth management, and institutional development. Upon joining Morningstar, she worked as a financial product support representative before transitioning to the Equity Research Department in March 2019. Prior to assuming the equity analyst role in 2021, Elfman was an associate equity analyst covering the cannabis industry.

Elfman holds a bachelor's degree in economics from Denison University.

Sponsor Center